US Pat. No. 10,212,961

SWEETENER COMPOSITIONS

DOUXMATOK LTD, Tel-Aviv ...

1. A sweetness enhancing composition comprising: a water dispersible, food-compatible, core particle consisting essentially of silica in direct intermolecular association with a sweetener carbohydrate having an enhanced sweetness as compared to a comparable amount of said carbohydrate in a free unassociated form.
US Pat. No. 10,213,473

MARINE PEPTIDES AND NUCLEOTIDES

Firmenich SA, Geneva (CH...

1. A method of reducing postprandial concentrations of glucose in a subject's blood comprising administering to the subject an effective amount of a combination of marine peptides and fish nucleotides sufficient to reduce the glucose concentration in the subject's blood, wherein the combination is administered to the subject prior to or during a meal; wherein the marine peptides and the fish nucleotides are present in a ratio of about 2:1 to about 10:1 by weight of the total weight of the combination; wherein the marine peptides are obtained by enzymatic hydrolysis of at least one marine protein and have a molecular weight in the range of from 1 to 20,000 Da; and wherein the fish nucleotides are extracted from tissue of fish, marine algae, crustaceans or shellfish and have less than 2% proteins comprising essentially of pure DNA or fragments thereof.
US Pat. No. 10,214,753

CHEMICAL ENGINEERING PROCESSES AND APPARATUS FOR THE SYNTHESIS OF COMPOUNDS

TEEWINOT TECHNOLOGIES LIM...

1. A bioreactor for producing cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA), wherein said bioreactor comprises: cannabigerolic acid (CBGA) and CBDA synthase; and wherein said bioreactor comprises a control mechanism configured to control conditions in the bioreactor to modify the ratio of CBDA to CBCA so produced wherein the control mechanism comprises addition of one or more organic solvents selected from the group consisting of dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), and isopropoyl alcohol; wherein the concentration of said solvent is maintained between 10% and 40% (v/v).
US Pat. No. 10,214,754

TRANSFORMANT AND ITS PRODUCTION PROCESS, AND METHOD FOR PRODUCING LACTIC ACID

JMTC Enzyme Corporation, ...

1. A transformant comprising:3 copies of a human lactate dehydrogenase gene that are introduced into a Schizosaccharomyces pombe host,
wherein a gene encoding pyruvate decarboxylase 2 of the Schizosaccharomyces pombe host is deleted or inactivated.
US Pat. No. 10,213,475

PEPTIDE FOR PREVENTING OR TREATING INFLAMMATORY DISEASES AND USE THEREOF

BIO PEP CO., LTD., Seoul...

1. A peptide consisting of the amino acid sequence of SEQ ID NO: 1, wherein the N- or C-terminal of the peptide is attached to a protective group selected from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or a polyethylene glycol (PEG) group.
US Pat. No. 10,213,987

RUBBER METAL LAMINATE

Unimatec Co., Ltd., Toky...

1. A rubber metal laminate comprising metal, an adhesive layer formed on the metal and a perfluoroelastomer layer formed on the adhesive layer, the perfluoroelastomer layer being formed from a vulcanizate layer of a blend comprising 2 to 5 parts by weight of a vinylidene fluoride-chlorotrifluoroethylene copolymer elastomer, based on 100 parts by weight of a perfluoroelastomer wherein the perfluoroelastomer is a copolymer of perfluorovinyl ether and at least one of tetrafluoroethylene and hexafluoropropene, the vulcanizate layer further comprises a filler.
US Pat. No. 10,214,499

DILUTE CHEMICAL REACTION PROCESS WITH MEMBRANE SEPARATION STEP

VLAAMSE INSTELLING VOOR T...

1. A process for carrying out a chemical reaction of a substrate (X) in a diluted reaction mixture comprising a solvent (S), the reaction being selected from a cyclisation reaction, a polymerization reaction, an enzymatic reaction showing substrate inhibition, an enzymatic reaction showing product inhibition, a reaction showing precipitation of the substrate or of the reactant, and combinations thereof, the process comprising the steps ofa) supplying a diluted substrate-solvent mixture to the inlet (3) of a reactor (2),
b) causing the substrate in the diluted reaction mixture in the reactor (2) to react,
c) discharging, from an outlet (4) of the reactor (2), reaction mixture comprising reaction product, solvent, and substrate that has not reacted,
d) conducting the reaction mixture to a first filtration membrane (6), with a retentate side (10) and a permeate side (11), whereby the first filtration membrane (6) is permeable to the solvent (S) and having a substrate (X) rejection of 80%-100%,
e) returning retentate (R) comprising substrate (X) that has not reacted, from the retentate side (10) of the first filtration membrane (6) to the reactor (2),wherein in step (a) said diluted substrate-solvent mixture is supplied to said inlet of said reactor from a diluting substrate feed system (5, 15) comprising an outlet connected to the inlet (3) of the reactor (2); wherein the diluting substrate feed system (5) for supplying substrate to the reactor (2) comprises a second filtration membrane (7) which is permeable to the solvent (S), wherein the permeability of the second filtration membrane (7) for the substrate (X) is selected such that the permeate (P2) of the second membrane has a concentration of the substrate (X) in the solvent (S), wherein permeate (P2) with the concentration of the substrate (X) in the solvent (S) is supplied from the permeate side (21) of the second filtration membrane (7) to the reactor (2);further comprising the step of returning solvent (S) which permeated the first filtration membrane (6) from the permeate side (11) of the first membrane (6) to said diluting substrate feed system (5, 15) to dilute the substrate in the diluting substrate feed system (5,15) thereby forming said diluted substrate-solvent mixture; and supplying a concentrated substrate solution from a substrate feed tank (18) to a mixing tank (19) in the diluting substrate feed system (5).
US Pat. No. 10,214,755

METHOD FOR PREPARING MERCAPTO FUNCTIONAL POLYESTER POLYOLS

NANJING TECH UNIVERSITY, ...

1. A method for preparing polyester polyol by using a micro-reaction device, wherein the micro-reaction device comprising a feed inlet, a micro mixer and a micro reactor connected in turn via a connecting tube;the method comprising the follow steps
(1) dissolving a lactone monomer into a first organic solution;
(2) dissolving a mercapto alcohol into a second organic solution;
(3) mixing the solution in step (1) with the solution in step (2) into a homogeneous mixture, and pumping the homogeneous mixture into the micro-reaction device for reacting for a sufficient amount of time to produce the polyester polyol compound where the micro-reactor comprises an immobilized enzyme; and
(4) recovering and purifying the polyester polyol;
wherein the lactone is a ?-valerolactone) or ?-caprolactone; the polyester polyol is a mercapto functional poly (?-valerolactone) or a mercapto functional poly (?-caprolactone).
US Pat. No. 10,213,989

METHOD OF MANUFACTURING A TIMBER COMPOSITE, THE TIMBER COMPOSITE OBTAINED AND DECORATIVE PANELS COMPRISING SUCH TIMBER COMPOSITE

GUANGZHOU AUSTRALIAN EUCA...

1. A method of manufacturing a timber composite, the method comprising the steps of:cutting one or more timber pieces to form a plurality of timber layers;
applying adhesive to the plurality of timber layers;
arranging the plurality of timer layers in a stack;
applying pressure to the timber layers; and
heating the timber layers,
such that the adhesive penetrates into the one or more timber layers and cures to form the timber composite, wherein the timber layers are arranged in the stack in their original order and orientation in the timber piece from which they are cut, and wherein the adhesive is a thermosetting adhesive.
US Pat. No. 10,214,758

METHOD AND COMPOSITIONS FOR IMPROVED LIGNOCELLULOSIC MATERIAL HYDROLYSIS

Wisconsin Alumni Research...

1. A method for digesting a non-wood biomass lignocellulosic material, wherein the method comprises:recombinantly expressing in a non-native microbial host cell SActE_0237 (GH6) (SEQ ID NO: 1), SActE_0265 (GH10) (SEQ ID NO: 5) and SActE_0236 GHQ48) (SEQ ID NO: 2),
isolating SActE_0237 (GH6) (SEQ ID NO: 1), SActE_0265 (GH10) (SEQ ID NO: 5) and SActE_0236 (GH48) (SEQ ID NO: 2) from the host cell, and
exposing the non-wood biomass lignocellulosic material to a sufficient amount of a composition comprising the isolated SActE_0237, SActE_0265, and SActE_0236,
wherein the exposed lignocellulosic material is at least partially digested.
US Pat. No. 10,213,479

COMPOUNDS AND METHODS FOR INCREASING HAIR GROWTH

The University of Kansas,...

1. A topical composition for increasing hair growth comprising:a pharmaceutical carrier configured for topical application to a subject; and
a polypeptide in the pharmaceutical carrier and having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4, wherein SPR4 is:
TVNAFYSASTNYPRSLSYGAIGVIVGHEFTHGFDNNGRGENIADNG (SEQ ID NO: 1),
wherein the SPR4 is present in a therapeutically effective amount for increasing hair growth in the subject when applied topically to the subject.
US Pat. No. 10,213,480

METHOD OF INHIBITING MICROGLIAL CELL MIGRATION AND TREATING TRAUMATIC BRAIN INJURY

BEECH TREE LABS, INC., D...

1. A method of inhibiting microglial cell migration in the brain of a mammalian subject suffering from traumatic brain injury (TBI) comprising administering an effective amount of streptolysin O (SLO) wherein microglial migration is inhibited.
US Pat. No. 10,213,481

COMPOSITIONS AND METHODS TO TREAT INFLAMMATORY JOINT DISEASE

1. A method of decreasing cartilage degradation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that binds to a ?-2,3-sialic acid transmembrane glycoprotein, wherein the agent is a lectin selected from the group consisting of Maackia plant lectin and Viscum plant lectin.
US Pat. No. 10,213,482

METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES

ImmuPharma France SA, Mu...

1. A method of treating or ameliorating a chronic inflammatory or hyper-chaperone-mediated-autophagy(CMA)-related disease or disorder, the method comprising administering to a patient in need thereof a composition comprising an effective amount of at least one peptide selected from the group consisting of SEQ ID NO:1, 2, 4, 5 and a combination thereof, wherein at least one serine in the peptide is phosphorylated, wherein the chronic inflammatory or hyper CMA-related disease or disorder is selected from the group consisting of muscular dystrophy (MD), fibromyalgia, myopathies, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), asthma, chronic pulmonary obstructive disorder (COPD), eosinophilic airway inflammation, and psoriasis, and the composition is effective in treating or ameliorating at least one symptom of the chronic inflammatory or hyper CMA-related disease or disorder.
US Pat. No. 10,214,762

CELL DIFFERENTIATION DEVICES AND METHODS

Georgia Tech Research Cor...

1. A method for separating live and dead cells in a sample comprising a mixed population of live and dead cells, the method comprising:(a) providing a microfluidic device, the microfluidic device comprising:
a first microfluidic channel comprising a laminar flow path, a first inlet positioned proximate a first end of the laminar flow path, a first outlet positioned proximate a second end of the laminar flow path, and a first static fluid collection chamber positioned adjacent to the laminar flow path;
a second microfluidic channel comprising a second inlet and a second outlet; and
a porous membrane disposed between the first and second microfluidic channels;
(b) flowing the sample into the first inlet, through the laminar flow path, and out of the first outlet; and
(c) flowing a first cellular stimulus into the second inlet, through the second microfluidic channel, and out of the second outlet, wherein at least a portion of the cellular stimulus diffuses out of the second microfluidic channel, through the porous membrane, and into the first microfluidic channel, thereby inducing a concentration gradient of the cellular stimulus such that the first static fluid collection chamber has a first concentration of cellular stimulus and the laminar flow path has a second concentration of cellular stimulus different from the first concentration,
wherein the concentration gradient causes live cells in the sample to migrate from the laminar flow path into the first static fluid collection chamber.
US Pat. No. 10,213,483

OLIGOPEPTIDIC COMPOUNDS AND USES THEREOF

APIM THERAPEUTICS AS, Tr...


wherein the oligopeptidic compound has 20-50 amino acids and comprises a cell penetrating signal sequence selected from the group consisting of SEQ ID NOs: 38-74, 129, 131 and 133, and wherein in said compound a PCNA interacting motif is N-terminal to said cell penetrating signal sequence.
US Pat. No. 10,213,995

MULTILAYERED COMPOSITE MATERIAL AND OBJECTS MADE THEREFROM

1. A multilayer composite having barrier properties for volatile organic compounds which have a vapor pressure of at least 0.01 kPa at 20° C. (293.15 K),wherein the multilayer composite has a first surface and a second surface and comprises at least one first layer and at least one further layer, wherein one of the two layers comprises at least one adsorption material for said volatile organic compounds and at least one polymeric support material in admixture with or bonded to the adsorption material, wherein if the at least one adsorption material and the at least one polymeric support material are bonded to one another, the composite comprises at least three layers, wherein
the polymeric support material comprises a high density polyethylene (HDPE), and wherein
the at least one adsorption material is selected from the group consisting of sheet and framework silicates, porous carbon material, metal organic frameworks (MOP) and mixtures thereof.
US Pat. No. 10,213,484

COMPOSITIONS FOR TREATING PATHOLOGICAL CALCIFICATION CONDITIONS, AND METHODS USING SAME

Yale University, New Hav...

1. An isolated cell comprising an ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) precursor polypeptide fusion, wherein the ENPP1 precursor polypeptide fusion comprises an ENPP1 polypeptide, an ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) signal peptide, and a stability domain, wherein the ENPP1 precursor polypeptide fusion is proteolytically processed upon secretion from the cell to yield a soluble ENPP1 polypeptide fusion comprising enzymatically active ENPP1 and the stability domain.
US Pat. No. 10,213,485

HGF PREPARATION SUITABLE FOR TREATMENT OF NEUROLOGICAL DISORDERS

KRINGLE PHARMA INC., Osa...

1. A hepatocyte growth factor (HGF) preparation which is obtained by freeze-drying of an aqueous solution comprising an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant, wherein the content of the lactose is in the range of 1 to 5 parts by weight relative to 1 part by weight of HGF,wherein the concentration of the lactose in the aqueous solution is in the range of 0.1 to 100 mg/mL,
wherein the concentration of the glycine in the aqueous solution is in the range of 0.1 to 10 mg/mL,
wherein the concentration of the HGF protein in the aqueous solution is in the range of 0.1 to 20 mg/mL,
wherein the concentration of the pH buffering agent in the aqueous solution is in the range of 1 to 20 mM,
wherein the pH buffering agent is a combination of citric acid or a hydrate thereof with a salt of citric acid and having the effect of keeping the pH of an HGF solution obtained by redissolving the HGF preparation within the range of 4.5 to 8.0,
wherein the surfactant is polysorbate,
wherein the concentration of the polysorbate in the aqueous solution is in the range of 0.005 to 1.0% by weight and
wherein the concentration of the sodium chloride in the aqueous solution is in the range of 150 to 1000 mM.
US Pat. No. 10,213,997

WATER-VAPOUR PERMEABLE COMPOSITE PARTS

Covestro Deutschland AG, ...

1. A water vapour-permeable flat composite component comprising:(i) at least one layer not consisting of thermoplastic polyurethane; and
(ii) at least one thermoplastic polyurethane layer composed of a polyether- and polyester-based thermoplastic polyurethane; wherein the thermoplastic polyurethane is the reaction product of the components consisting of:
A) at least one organic diisocyanate;
B) at least one component having two hydroxyl groups and in each case having a number-average molecular weight of 60 to 490 g/mol as chain extender;
C) a component consisting of one or more polyether polyols each having a number-average molecular weight of 500-5000 g/mol, of which at least one polyether polyol (C1) contains ethylene oxide units; and
D) 10% to 85% by weight, based on the total weight of C) and D), of one or more aliphatic polyester polyols each having a number-average molecular weight of 500-5000 g/mol;
wherein the molar ratio of the NCO groups in A) to isocyanate-reactive groups in B), and D) is 0.9:1 to 1.2:1;
wherein the total content of ethylene oxide units in component C) is at least 5% and not more than 45% by weight, based on the total weight of components C) and D), and the number-average functionality of the sum total of all the polyols in C) and D) is 1.8 to 2.5, and wherein the content of ethylene oxide units (X in % by weight) in component C), relative to the molar ratio Y of chain extenders B) to the sum total of components C) and D), is below the value of X according to the formula X (% by weight)=7.35*Y+13.75.
US Pat. No. 10,213,486

FORMULATIONS OF DILUTED AMINO ACID SEGMENTS AND METHODS FOR MAKING SAME

Deseret Biologicals, Inc....

1. A method comprising:mixing an amino acid fragment and a diluting agent to form a mixture; and
serially diluting at least a portion of the mixture to produce a diluted formulation having a concentration of the amino acid fragment that is no more than 1×10?10 w/w;
wherein the amino acid fragment includes a peptide sequence of at least five amino acids that is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin; and
wherein the amino acid fragment is not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin.
US Pat. No. 10,213,487

NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIA

Eli Lilly and Company, I...

1. A powder composition comprising glucagon (SEQ ID NO: 1), a phospholipid, and ß-cyclodextrin, wherein the ratio of glucagon to phospholipid to ß-cyclodextrin is 1:1:8 by weight.
US Pat. No. 10,213,488

DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN

The Board of Trustees of ...

1. A method of treating hyperparathyroidism comprising administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject in need of treatment for hyperparathyroidism, wherein the bacterial collagen-binding polypeptide segment comprises a collagen-binding polypeptide derived from an M9 peptidase selected from the group consisting of: SEQ ID NOs: 13-34, a fragment of at least 8 consecutive amino acids of SEQ ID NOs: 13-34, residues 34-158 of SEQ ID NO: 1, a fragment of at least 8 consecutive amino acids from residues 34-158 of SEQ ID NO: 1, a peptide that is at least 90% identical to residues 34-158 of SEQ ID NO: 1, and a peptide that is at least 90% identical to SEQ ID NOs: 13-34 and wherein the PTH/PTHrP receptor agonist comprises residues 1-33 of SEQ ID NO: 1, PTH (SEQ ID NO: 7), residues 1-14 of SEQ ID NO: 7, residues 1-34 of SEQ ID NO: 7, residues 1-7 of SEQ ID NO: 7 or a fragment of at least 8 consecutive amino acids from residues 1-34 of SEQ ID NO: 7.
US Pat. No. 10,213,489

THREE DIMENSIONAL HEALING KIT

1. A three-dimensional healing kit comprising a fibrin generation apparatus containing a network structured apparatus and a carrier rod and a fibrin compression apparatus;wherein the fibrin generation apparatus is separated from the fibrin compression apparatus, and the fibrin generation apparatus is inserted into a tube to perfume a centrifugation to separate a fibrin on the network structured apparatus from blood;
the network structured apparatus comprises an agent for accelerating a platelet aggregation and formation of the fibrin; and wherein the fibrin contacts with the agent to form a platelet rich fibrin, and the agent is one or more selected from the group consisting of calcium phosphate compounds, titanium, collagen, bioceramics and resorbable polymers.
US Pat. No. 10,214,769

METHOD FOR DESIGNING PROBE IN DNA MICROARRAY, AND DNA MICROARRAY PROVIDED WITH PROBE DESIGNED THEREBY

TOYOTA JIDOSHA KABUSHIKI ...

1. A method for detecting a mutation using a DNA microarray having a plurality of polynucleotide probes immobilized thereon, said method comprising the steps of:extracting a genomic DNA derived from an organism to be tested;
digesting the genomic DNA with a restriction enzyme having the same recognition sequence as a restriction enzyme used to design the probes immobilized on the DNA microarray;
connecting an adaptor to the genomic DNA fragments obtained by the restriction enzyme treatment;
amplifying the genomic DNA fragments using a primer capable of hybridizing to the adaptor; and
detecting a hybrid of a genomic DNA fragment containing a mutation with a probe capable of detecting the mutation, by bringing the amplified genomic DNA fragment into contact with the DNA microarray,
wherein said DNA microarray comprises a plurality of probes, and a carrier on which the probes are immobilized, wherein said plurality of probes is capable of detecting a mutation contained in a genomic DNA fragment obtained by said digesting, wherein the plurality of polynucleotide probes comprises probes covering different portions of the genomic DNA fragment, wherein the plurality of polynucleotide probes covers the entire region of the genomic DNA fragment, and wherein the probes in said plurality of polynucleotide probes are shorter in length than the genomic DNA fragment.
US Pat. No. 10,213,490

COMPOSITIONS FOR PROVIDING AGENTS THAT DEGRADE IN WATER

Virun, Inc., Pomona, CA ...

1. An emulsion composition, comprising:a) an agent for delivery, wherein the agent is a probiotic;
b) a delivery vehicle associated with the agent, wherein the delivery vehicle is selected from among a micelle, inverse micelle, liposome, cubosome and a mixture thereof; and
c) a mucoadhesive protein associated with the delivery vehicle and/or agent,wherein:the mucoadhesive protein is present at a concentration of about 1%, by weight, up to about 50% of the total weight of the composition;
the mucoadhesive protein is selected from among the family of transferrins and the family of mucin proteins, whereby the composition can adsorb to the mucosa for effecting systemic delivery of the agent;
the mucoadhesive protein is associated with the delivery vehicle and/or the agent via a chemical or physical bond;
the composition is formulated as an emulsion and is formulated for mucosal delivery to the oral or gastrointestinal tract mucosa; and
the emulsion comprises an oil phase, and a polar phase comprising a polar protic solvent other than water, whereby the emulsion does not contain water.
US Pat. No. 10,214,770

COMPOSITIONS AND METHOD FOR MEASURING AND CALIBRATING AMPLIFICATION BIAS IN MULTIPLEXED PCR REACTIONS

ADAPTIVE BIOTECHNOLOGIES ...

1. A method for quantifying a plurality of rearranged nucleic acid molecules encoding one or a plurality of adaptive immune receptors in a biological sample that comprises rearranged nucleic acid molecules from lymphoid cells of a mammalian subject, each adaptive immune receptor comprising a variable (V) region and a joining (J) region, the method comprising:(A) amplifying nucleic acid molecules in at least one multiplex polymerase chain reaction (PCR) that comprises:
(1) rearranged nucleic acid molecules from the biological sample that comprises lymphoid cells of the mammalian subject,
(2) a composition, comprising a plurality of synthetic template oligonucleotides comprising sequences of rearranged nucleic acid molecules encoding one or more adaptive immune receptors and at least one unique oligonucleotide barcode sequence such that each synthetic template oligonucleotide has a unique oligonucleotide sequence and wherein a known number of each of the plurality of synthetic template oligonucleotides having a unique oligonucleotide sequence is present,
(3) an oligonucleotide amplification primer set comprising:
a plurality of V-segment oligonucleotide primers and a plurality of J-segment oligonucleotide primers, wherein the primer set is capable of promoting amplification in said at least one multiplex polymerase chain reaction (PCR) of
(i) substantially all synthetic template oligonucleotides in the composition to produce a multiplicity of amplified synthetic template oligonucleotides, said multiplicity of amplified synthetic template nucleic acid molecules being sufficient to quantify diversity of the synthetic template oligonucleotides in the composition, and
(ii) substantially all rearranged nucleic acid molecules encoding adaptive immune receptors in the biological sample to produce a multiplicity of amplified rearranged nucleic acid molecules, said multiplicity of amplified rearranged nucleic acid molecules being sufficient to quantify diversity of the rearranged nucleic acid molecules in the nucleic acid from the biological sample,
(B) quantitatively sequencing said amplified synthetic template oligonucleotides and said amplified rearranged nucleic acid molecules to quantify
(i) a synthetic template product number of amplified template oligonucleotides which contain the at least one unique oligonucleotide barcode sequence, and
(ii) a rearranged product number of amplified rearranged nucleic acid molecules which lack a unique oligonucleotide barcode sequence;
(C) calculating an amplification factor by dividing the synthetic template product number of (B)(i) by the known number of each of the plurality of synthetic template oligonucleotides having at least one unique barcode oligonucleotide sequence of (A)(2); and
(D) dividing the rearranged product number of (B)(ii) by the amplification factor calculated in (C) to quantify the number of unique adaptive immune receptor encoding rearranged nucleic acid molecules in the sample.
US Pat. No. 10,214,771

DNA AMPLIFICATION AND SEQUENCING USING DNA MOLECULES GENERATED BY RANDOM FRAGMENTATION

Takara Bio USA, Inc., Mo...

1. A method of preparing a population of DNA fragments, comprising:(a) fragmenting a DNA molecule to produce DNA fragments;
(b) producing a homopolymer extension on 3? ends of the DNA fragments; and
(c) amplifying a plurality of the fragments with a population of primers complementary to a known sequence in the DNA fragments and a population of primers comprising a region complementary to the homopolymer extension, wherein a portion of each primer in the population of primers comprising a region complementary to the homopolymer extension comprises a random sequence.
US Pat. No. 10,213,492

TREATMENT FOR MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY (MNGIE)

1. A method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain bacterial thymidine phosphorylase and are free of animal proteins other than proteins derived from the patient, said animal proteins comprise BSA, wherein the number of autologous erythrocytes is from 50×1010 to 92×1010, wherein the autologous erythrocytes comprise less than 200 EU of endotoxin per mg of bacterial thymidine phosphorylase, wherein the bacterial thymidine phosphorylase is administered to the patient at a concentration of less than 300 IU of bacterial thymidine phosphorylase per 1×1010 erythrocytes, thereby treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in the patient.
US Pat. No. 10,213,748

PORE OPENED ZEOLITE NANOSHEETS AND THEIR SUSPENSIONS AND METHODS AND USES RELATED THERETO

Regents of the University...

1. A method, comprising:exposing a multi-lamellar (ML) zeolite material comprising an organic structure directing agent (OSDA) to a mixture comprising sulfuric acid and hydrogen peroxide under conditions sufficient to remove substantially all of the OSDA from the ML zeolite material; and
after exposing the ML zeolite material, treating a solution containing the ML zeolite material to sonication and/or mixing under conditions sufficient to substantially exfoliate layers of the ML zeolite to obtain porous two-dimensional zeolite nanosheets that are substantially free of the OSDA.
US Pat. No. 10,214,773

SIMULTANEOUS DETECTION OF TARGET PROTEIN AND TARGET NUCLEIC ACIDS IN A SINGLE CELL

Fluidigm Corporation, So...

1. A kit for performing a multiplexed assay of RNA and protein from a sample, the kit comprising:a) at least one pair of protein-detecting proximity probes, wherein each pair of protein-detecting proximity probes comprises:
a first protein-detecting probe comprising a first antibody that binds to a target protein joined to a first polynucleotide that comprises an I segment at the 3? end that is complementary to an I segment on the 3? end of a second probe; and
a second protein-detecting probe comprising a second antibody that binds to the target protein joined to a second polynucleotide that comprises an I segment complementary to the I segment at the 3? end of the first polynucleotide of the first probe;
wherein binding of the first antibody to the target protein and binding of the second antibody to the target protein allows the I segment of the first protein proximity probe to hybridize to the I segment of the second protein proximity probe to form a duplex;
b) a polymerase for extending the duplex to provide an extended product; and
c) primers that together amplify the extended product, or subregion thereof; and amplify two or more target nucleic acid sequences in the same reaction mixture.
US Pat. No. 10,213,494

TREATMENT OF SYNUCLEINOPATHIES

Genzyme Corporation, Cam...

1. A method of treating a subject with a synucleinopathy, but not a clinically diagnosed lysosomal storage disease, wherein the synucleinopathy comprises any one or more of: sporadic or heritable dementia with Lewy bodies (DLB); pure autonomic failure (PAF) with ?-synuclein deposition; multiple system atrophy (MSA); hereditary neurodegeneration with brain iron accumulation; incidental Lewy body disease of advanced age; Down's syndrome; progressive supranuclear palsy; essential tremor with Lewy bodies; tau gene and progranulin gene-linked dementia without parkinsonism; Creutzfeldt Jakob disease; bovine spongiform encephalopathy; sporadic or heritable spinocerebellar ataxia; and idiopathic rapid eye movement sleep behavior disorder, the method comprising administering to a subject any one or more of:a prosaposin polypeptide;
a polynucleotide encoding a prosaposin polypeptide;
a saposin A, B, or D polypeptide; and
a polynucleotide encoding a saposin A, B, or D polypeptide;in an amount effective to reduce a level of a-synuclein in the subject's nervous system or in the subject's lysosomal compartment.
US Pat. No. 10,214,774

METHOD OF DETERMINING THE NUCLEOTIDE SEQUENCE OF OLIGONUCLEOTIDES AND DNA MOLECULES

LIFE TECHNOLOGIES CORPORA...

1. A method for phase error compensation during nucleic acid sequencing, comprising:providing a plurality of template nucleic acid strands;
performing a first series of sequential nucleotide incorporation reactions resulting in one or more nucleotide incorporations into the plurality of template nucleic acid strands, the nucleotide incorporation reactions using a sequence of individual deoxynucleoside triphosphates introduced to react with the template nucleic acid strands;
after each incorporation reaction detecting a signal transmitted from the incorporation of the one or more nucleotides, the signal having an amplitude corresponding to a number of nucleotide incorporations;
in response to identifying an error component of the detected signal that is attributable to a fraction of the template nucleic acid strands that are out of phase based on extension of the template nucleic acids strands resulting from nucleotide incorporations, subtracting the error component of the detected signal from the detected signal to obtain a corrected detected signal, thereby maintaining the sequencing of the plurality of template nucleic acid strands.
US Pat. No. 10,214,775

PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS

Chronix Biomedical, San ...

1. A method of analyzing circulating cell-free DNA in a sample from a patient that has or is suspected of having prostate cancer, comprising measuring, in a sample that is blood, serum or plasma, the level ofa first cell-free DNA having a sequence at least 25 nucleotides in length unambiguously assigned to a first chromosomal region set forth in Table 4, and
a second cell-free DNA having a sequence at least 25 nucleotides in length unambiguously assigned to a second chromosomal region set forth in Table 4 that is different from the first,
wherein the sequences of said first and second cell-free DNAs are free of repetitive elements.
US Pat. No. 10,213,496

REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF

EPIVAX, INC., Providence...

1. A method of inducing regulatory T-cells to suppress immune response in a subject comprising administrating to the subject a therapeutically effective amount of a T-cell epitope composition, wherein the T-cell epitope composition comprises one or more isolated T-cell epitope polypeptides, wherein at least one isolated T-cell epitope polypeptide consists of the amino acid sequence of SEQ ID NO: 4.
US Pat. No. 10,214,776

NANOPROBE-BASED GENETIC TESTING

Agency for Science, Techn...

7. A kit comprising a first and second conjugate,the first conjugate comprising a first nanoparticle and a first oligonucleotide analog, wherein the first oligonucleotide analog is a phosphorodiamidate morpholino oligo or a derivative thereof that is covalently coupled to the first nanoparticle, and
the second conjugate comprising a second nanoparticle and a second oligonucleotide analog, wherein the second oligonucleotide analog is a phosphorodiamidate morpholino oligo or a derivative thereof that is covalently coupled to the second nanoparticle,
wherein the first oligonucleotide analog differs from the second oligonucleotide analog by at least one nucleobase and wherein the first oligonucleotide analog has a sequence identity to the second oligonucleotide analog of at least 85%,
wherein
the first oligonucleotide analog comprises the base sequence set forth in SEQ ID NO: 1 and the second oligonucleotide analog comprises the base sequence set forth in SEQ ID NO: 2.
US Pat. No. 10,219,388

METHODS OF TRANSFERRING ELECTRICALLY CONDUCTIVE MATERIALS

PPG Industries Ohio, Inc....

1. A method of transferring an electrically conductive material to a substrate, the method comprising:a) contacting at least a portion of a non-planar substrate with a layered structure comprising:
(1) a dielectric material layer positioned over a carrier film;
(2) an electrically conductive material layer comprising the electrically conductive material positioned over the dielectric material layer; and
(3) an adhesive layer positioned over the electrically conductive material layer; and
b) applying heat and pressure to the substrate and carrier film for a period of time ranging from 1 to 40 seconds, at a temperature ranging from 200° F. to 450° F., and at a pressure ranging from 30 to 150 psi, such that the electrically conductive material layer adheres to the substrate.
US Pat. No. 10,213,497

VACCINE

1. A pharmaceutical composition comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 121, 124, 126, 130, 131, and 134.
US Pat. No. 10,214,777

MOLECULAR DIAGNOSTIC TEST FOR CANCER

Almac Diagnostics Limited...

1. A method of diagnosing and treating an individual as having a DNA damage response deficient (DDRD) cancer comprising;a. measuring expression levels of at least two genes in a test sample of tumour cells obtained from the individual to determine a test score, wherein the at least two genes are selected from the group consisting of CXCL10, IDO1, CD2, GBP5, ITGAL, LRP4, APOL3, CDR1, FYB, TSPAN7, RAC2, KLHDC7B, GRB14, AC138128.1, KIF26A, CD274, CD109, ETV7, MFAP5, OLFM4, PI15, FOSB, FAM19A5, NLRC5, PRICKLE1, EGR1, CLDN10, ADAMTS4, SP140L, ANXA1, RSAD2, ESR1, IKZF3, OR2I1P, EGFR, NAT1, LATS2, CYP2B6, PTPRC, PPP1R1A, and AL137218.1; and
b. treating the individual with a DNA-damage therapeutic agent, wherein the individual is diagnosed as having the DDRD cancer because a test score of the test sample exceeds a threshold score, and said exceeding occurs if the test score, based on the expression levels of the at least two genes, exceeds a threshold score based on the same genes.
US Pat. No. 10,213,498

PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprisingadministering to said patient a population of activated T cells that selectively recognize cells that aberrantly express a peptide consisting of the amino acid sequence of VLLDTILQL (SEQ ID NO: 38),
wherein said cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), chronic lymphocytic leukemia (CLL), breast cancer (BRCA), esophageal cancer, urinary bladder cancer, uterine cancer, gallbladder cancer, bile duct cancer, acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and ovarian cancer (OC).
US Pat. No. 10,214,778

METHODS AND NUCLEOTIDE FRAGMENTS OF PREDICTING OCCURRENCE, METASTASIS OF CANCERS AND PATIENTS' POSTOPERATIVE SURVIVAL IN VITRO

Beijing Institute For Can...

1. A method of detection of metastasis of cancers and postoperative survival in a human having gastric cancer, colon cancer or hepatocellular carcinoma, characterized in that said method comprises the following steps:a) extracting gastric, colon or liver tissue DNA or plasma free DNA samples from a certain number of patients with metastatic cancer and patients with non-metastatic cancer;
b) detecting and calculating the proportion of methylated or demethylated GFRa1 CpG islands in the promoter region of GFRa1 of said DNA from a); setting a cutoff value for detection of metastasis of cancers and patients' postoperative survival using-the proportion of methylated or demethylated GFRa1, wherein the cutoff value of methylated or demethylated GFRa1 is calculated by using a Receiver Operating Characteristic (ROC) curve;
c) extracting gastric, colon or liver tissue DNA or plasma free DNA samples from human testing subjects, detecting and calculating the proportion of methylated or demethylated GFRa1 CpG islands in the DNA samples;
d) comparing the proportion of methylated or demethylated GFRa1 determined in the step c) with the cutoff value set in the step b); and
e) detecting the metastasis of cancers and patients' postoperative survival based on the detection of a less than or equal proportion of methylated GFRa1 CpG islands determined in step c) as compared to the cutoff value set in the step b), or based on the detection of a higher than or equal proportion of demethylated GFRa1 CpG islands determined in step c) as compared to the cutoff value set in the step b), wherein the proportion of the methylated or demethylated GFRa1CpGs islands is determined and calculated by DHPLC or bisulfate-sequencing using following primer sets:
i) the primer pair set forth in SEQ ID NO: 5 and SEQ ID NO: 6; or
ii) the primer pair set forth in SEQ ID NO: 7 and SEQ ID NO: 8.
US Pat. No. 10,213,499

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS

1. A method of treating cancer in a HLA-A*02+ patient having a cancer overexpressing a ABCC11 polypeptide comprising the amino acid sequence of SEQ ID NO: 7 and presenting at its surface a peptide consisting of SEQ ID NO: 7 in the context of a complex with an MHC class I molecule, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate the cancer cells, wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 7 in the context of a complex with an MHC class I molecule in vitro, wherein said cancer is selected from the group consisting breast cancer, acute myeloid leukemia, and hepatocellular carcinoma.
US Pat. No. 10,214,779

METHOD FOR IDENTIFICATION OF ANTI-HIV HUMAN MIRNA MIMICS AND MIRNA INHIBITORS AND ANTI-HIV PHARMACEUTICAL COMPOUNDS

CSIR, Pretoria (ZA)

1. A method for the identification of pharmaceutical compounds targeting cellular pathways associated with cancer, which are effective in the treatment of HIV infection, comprising:a) providing a first batch of reporter cells and providing a panel of miRNAs,
wherein the reporter cells are osteosarcoma cells comprising a reporter gene driven by an HIV LTR promoter,
wherein the reporter cells are divided into a first batch of plurality of samples and
wherein each of the first batch of plurality of samples is transfected with an miRNA from the panel;
b) infecting the transfected samples with HIV;
c) screening the infected samples to identify one or more miRNAs that inhibit or protect against the HIV infection when the infected samples show an equal or a lower expression of the reporter gene than a control and to identify one or more miRNAs that promote the HIV infection when the infected samples show a higher expression of the reporter gene than the control,
d) identifying a specific cellular pathway, a polynucleotide and/or a polypeptide, which is targeted by the identified one or more miRNAs, from c);
e) identifying one or more anti-cancer pharmaceutical compounds, which have anti-cancer activity against the identified cellular pathway, polynucleotide and/or polypeptide of d);
f) providing a second batch of the reporter cells,
wherein the second batch of the reporter cells are divided into a second batch of plurality of samples and
wherein each of the second batch of plurality of samples is treated with the identified one or more anti-cancer pharmaceutical compounds in e);
g) infecting the second batch of plurality of samples with HIV, wherein the infecting occurs before or after the treatment with the identified one or more anti-cancer pharmaceutical compounds; and
h) identifying the pharmaceutical compounds effective in the treatment of the HIV infection when the infected samples treated with the identified one or more anti-cancer pharmaceutical compounds show a lower expression of the reporter gene than the control wherein the miRNAs are selected from the group consisting of hsa-let-7a-5p, hsa-let-7d-5p, hsa-miR-23a, hsa-mir-29c*, hsa-miR-34c-3p, hsa-mir-124a-3p, hsa-miR-124a, hsa-miR-138, hsa-miR-146a, hsa-miR-149-3p, hsa-miR-150, hsa-miR-155, hsa-miR-193b-5p, hsa-miR-200c, hsa-miR-421, hsa-miR-423-3p, hsa-miR-504, hsa-miR-637, hsa-mir-650, and hsa-miR-1200.
US Pat. No. 10,217,084

SYSTEM FOR PROCESSING RESOURCE DEPOSITS

Bank of America Corporati...

1. A system for processing resource deposits, the system comprising:a memory device; and
one or more processing devices operatively coupled to the memory device, wherein the one or more processing devices are configured to execute computer-readable program code to:
provide a container comprising a unique identifier tag to a merchant;
provide a deposit application to the merchant for installation on a remote computing device of the merchant;
receive, from the computing device of the merchant, an indication that the unique identifier tag of the container has been scanned by the computing device of the merchant;
in response to receiving the indication that the unique identifier tag of the container has been scanned, transmit a deposit alert over a communication channel to the computing device of the merchant, wherein the deposit alert activates the deposit application to display a deposit portal comprising input fields and a request for the merchant to provide a merchant input associated with contents of the container;
receive, from the computing device of the merchant, the merchant input associated with the contents of the container; and
store the received merchant input associated with the contents of the container in a deposit database.
US Pat. No. 10,213,500

MULTICOMPONENT OR MONOCOMPONENT VACCINE TO BE USED AGAINST CHAGAS DISEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE OBTENTION OF IMMUNOGEN OF SAID VACCINES, AND NUCLEIC ACID USED IN SAID PROCEDURE

1. A monocomponent vaccine effective to moderate the clinical consequences of Chagas disease, said vaccine comprising, as active ingredient, an immunogenic component comprising a polynucleotide, said nucleotide encoding one or more polypeptide(s) each having a C-terminal region composed of at least two repetitive units of amino acids and a eukaryotic promoter operably linked to one or more coding regions for said polypeptide(s), wherein each repetitive unit of amino acids shows the following amino acid sequence:AHSTPSTPVDSS (SEQ ID NO: 6)
and wherein a polypeptide with trans-sialidase activity of Trypanosoma cruzi is fused to the C-terminal region of each of said polypeptide(s), wherein the polypeptide with trans-sialidase activity of Trypanosoma cruzi has the amino acid sequence of SEQ ID NO. 2 and is encoded by the nucleotide sequence of SEQ ID NO. 1, and
wherein the vaccine further comprises an adjuvant that does not inhibit trans-sialidase enzymatic activity of the immunogen portion, wherein the adjuvant is aluminum oxide.
US Pat. No. 10,214,780

METHOD AND MEANS FOR IDENTIFICATION OF ANIMAL SPECIES

CITY UNIVERSITY OF HONG K...

1. A method of rapid identification of a mammalian species origin or mammalian species origins of a sample, comprising sequential steps of:a) engineering DNA probes with a length from 60 to 80 bases; said engineering including identifying regions from 48th to 705th bp of double stranded COI gene region of a first mammalian species for yielding a first group of 60-80 bp DNA regions of interest, and from the first group of 60-80 bp of DNA regions of the double stranded COI gene region, identifying a second group of 60-80 bp DNA regions of single-stranded sequences of the double stranded COI gene region meeting a combination of the following criteria:
i) with a GC content 50 to 52%;
ii) with a positive value of delta G at a given temperature, wherein the given temperature is a hybridization temperature (Thyb) of 15-25° C. below a melting temperature (Tm), wherein the hybridization temperature (Thyb) is a temperature at which the DNA probes hybridize during identification, and wherein the melting temperature (Tm) is a temperature at which the double stranded sequence at a region corresponding to the second group of 60-80 bp DNA regions dissociates; and
iii) in which difference between the number of secondary structures (SS) of any of the DNA regions in the second group of 60-80 bp DNA regions and the value of secondary structure (SS) of the respective DNA region is between 0 to 4, thus yielding a third group of DNA regions, wherein the value of the secondary structure is determined based on propensity of a base of single-stranded DNA molecules;
b) producing the DNA probes corresponding to sequences of the third group of DNA regions, wherein the sequences of the DNA probes are comprised in the group consisting of SEQ ID NOs. 1-241;
c) collecting the sample;
d) dividing the sample into a number of portions for situation in a multi-well container or containers;
e) providing the produced DNA probes from step b), wherein the number of the sample portions is greater than the number of mammalian species types from which the DNA probes derive;
f) selecting some or all of the DNA probes, and allocating the selected DNA probes in the multi-well container or the containers, such that each of the selected DNA probes is situated separately, for hybridization with the sample portions, respectively;
g) contacting the sample portions for intended hybridization with the selected DNA probes simultaneously;
h) analyzing the sample portions contained in the multi-well container or containers for a positive hybridization results following the contacting step; and
i) determining the mammalian species origin or origins of the sample according to positive hybridization results.
US Pat. No. 10,213,501

THREE-COMPONENT-MULTISTAGE MALARIA VACCINE

Fraunhofer-Gesellschaft z...

1. A mixture of recombinant proteins as an immunogenic composition for inducing an immune response in a human against the parasite Plasmodium falciparum, wherein the mixture comprises:a) a first recombinant fusion protein (fusion protein 1) comprising PfAMA1-DICO1, Pfs25 and PfCSP_TSR;
b) a second recombinant fusion protein (fusion protein 2) comprising PfAMA1-DICO2, Pfs25 and PfMSP1-19; and
c) a third recombinant fusion protein (fusion protein 3) comprising PfAMA1-DICO3, Pfs25 and a PfRh5 peptide.
US Pat. No. 10,214,781

LPS SEROTYPES FOR DETERMINING SEVERITY OF URINARY TRACT INFECTION

1. A method of identifying and treating a subject having no underlying anatomical urinary tract infection (UTI) etiology for a urinary tract infection having a significant risk of dangerous sequalae, comprising:obtaining a urine or fecal sample from the subject;
detecting the predominant LPS O-antigen serotype in the sample using an analytic device;
and treating the UTI of the subject if the predominant O-antigen LPS serotype is a febrile Escherichia coli UTI LPS serotype.
US Pat. No. 10,214,782

METHODS AND KITS TO IDENTIFY KLEBSIELLA STRAINS

The Translational Genomic...

1. A method of detecting carbapenem-resistant Enterobacteriaceae in a sample, the method comprising the steps of:adding to a mixture comprising the sample a first oligonucleotide consisting of SEQ ID NO: 1, a second oligonucleotide consisting of SEQ ID NO: 2, and a third oligonucleotide consisting of SEQ ID NO: 3;
subjecting the mixture to conditions that allow nucleic acid amplification; and
detecting the carbapenem-resistant Enterobacteriaceae in the sample by detecting nucleic acid amplification in the mixture.
US Pat. No. 10,213,503

ATTENUATED BURKHOLDERIA MALLEI STRAIN WHICH PROTECTS AGAINST PATHOGENIC BURKHOLDERIA INFECTIONS, VACCINE CONTAINING AND USE THEREOF

THE BOARD OF TRUSTEES OF ...

1. A live attenuated Burkholderia strain containing mutations which result in the disruption in the expression or functionality of the gene products encoded by the tonB gene and the hcp1 gene, wherein the Burkholderia strain is Burkholderia mallei strain or Burkholderia pseudomallei strain.
US Pat. No. 10,214,783

ENDPOINT ZYGOSITY ASSAY TO DETECT RF4 GENE IN MAIZE

Dow AgroSciences LLC, In...

1. A PCR assay method for determining zygosity of an Rf4 gene in a corn plant, the method comprising:(a) performing a first PCR assay using a first probe, a first forward primer, and a first reverse primer on a polynucleotide from a corn plant sample, wherein the first probe is SEQ ID NO:3;
(b) performing a second PCR assay using a second probe, a second forward primer, and a second reverse primer on the polynucleotide sample, wherein the second probe is SEQ ID NO:4;
(c) quantifying the first probe and the second probe; and,
(d) comparing the quantified first probe and the quantified second probe of the first PCR assay and the second PCR assay to determine the zygosity,
wherein the zygosity of the Rf4 gene in the corn plant is selected from the group consisting of homozygous, heterozygous, hemizygous, and nullizygous.
US Pat. No. 10,217,600

INDIRECTLY HEATED CATHODE ION SOURCE ASSEMBLY

ION TECHNOLOGY SOLUTIONS,...

1. An indirectly heated cathode ion source assembly for use in creating a stream of ions comprisinga cathode cup unit having a disc-shaped body, a pair of semicircular elements concentric to and holding said body therebetween and a cylindrical retainer concentrically housing said body and said elements and forming a thermal reflector;
a thermal barrier having a plurality of cylindrical foils concentric to said retainer of said cathode cup unit to reduce thermal loss;
a filament coaxially disposed within said cathode cup unit for generating thermal electrons at a face thereof spaced from said body a predetermined distance, said filament having a pair of parallel leads supporting said face;
a graphite support plate having said leads of said filament passing therethrough; and
a thermal reflector mounted on said graphite support plate in spaced relation to said face of said filament and with said leads of said filament passing therethrough.

US Pat. No. 10,218,967

DISPLAY DEVICE AND METHOD FOR DRIVING THE SAME

Semiconductor Energy Labo...

1. A display device comprising:a display panel comprising a first pixel region for a left eye of a viewer and a second pixel region for a right eye of the viewer;
a shutter panel comprising a liquid crystal layer;
a detector configured to detect a position of the viewer; and
a control device comprising an image signal generation circuit and a parallax barrier control circuit,
wherein the control device is electrically connected to the display panel, the shutter panel and the detector,
wherein the display panel and the shutter panel overlap each other,
wherein the parallax barrier control circuit is configured to form a parallax barrier in the shutter panel by switching the liquid crystal layer from a light-transmitting state to a light-blocking state,
wherein the image signal generation circuit is configured to output an image signal to the display panel, and
wherein the image signal generation circuit is configured to vary the image signal in accordance with the position of the viewer.

US Pat. No. 10,218,964

DIMENSIONING SYSTEM WITH FEEDBACK

HAND HELD PRODUCTS, INC.,...

1. A method, comprising:receiving, with a processor, range data from a dimensioning subsystem;
creating, with the processor, a distance map from the received range data;
determining, with the processor, a null-data pixel-count from the distance map, the null-data pixel-count comprising a sum total of null-data pixels; and
computing, with the processor, a dimension measurement if the null-data pixel-count is at or below a threshold count, or
generating, with the processor, an error feedback if the null-data pixel-count is above the threshold count.

US Pat. No. 10,218,952

ARCHITECTURE FOR RENDERING HIGH DYNAMIC RANGE VIDEO ON ENHANCED DYNAMIC RANGE DISPLAY DEVICES

Microsoft Technology Lice...

1. A computer system comprising one or more processing units and memory, wherein the computer system implements a video playback system that includes:decision logic configured to:
receive an indication of a peak brightness of a target display device;
determine if the peak brightness of the target display device is above a first peak brightness threshold and below a second peak brightness threshold, wherein the first peak brightness threshold is defined to be at or above a peak brightness of 100 nits, for a standard dynamic range (“SDR”) display device, and wherein the second peak brightness threshold is defined to be at or below a peak brightness of 4000 nits, for a high dynamic range (“HDR”) display device; and
if so, select an HDR-to-enhanced dynamic range (“EDR”) tone mapping mode;
a streaming controller configured to request encoded data for HDR video;
an input buffer configured to store the encoded data;
a video decoder configured to decode the encoded data, and thereby produce sample values of HDR video; and
a tone mapper configured to apply tone mapping to input values for the sample values of HDR video, according to a tone mapping function that is based at least in part on the peak brightness of the target display device, and thereby produce output values for sample values of EDR video.

US Pat. No. 10,218,950

METHOD AND APPARATUS FOR PROJECTING IMAGES ON ARTIFICIAL WINDOWS

1. A method for creating a plurality of simulated window views on an interior surface of a building comprising the steps of:define an array of spaced apart window dimensioned areas on the surface that will simulate actual windows,
provide at least one short throw video projector in close proximity to each of the simulated windows,
provide a video recording of an image to be viewed on the array,
map the video recording to create discrete segments of the video recording assigned to separate ones of the array of simulated windows,
direct the mapped video segments to the at least one projector in proximity to the simulated window to which the video segment is assigned.

US Pat. No. 10,218,945

IMAGE SENSOR AND IMAGE-CAPTURING DEVICE

NIKON CORPORATION, Tokyo...

1. An image sensor comprising:a first microlens;
a first filter that is transmissive to a first wavelength of light having passed through the first microlens;
a first photoelectric converter that generates charges by performing photoelectric conversion of the first wavelength light transmitted through the first filter;
a second filter that is transmissive to a second wavelength of the light having passed through the first microlens;
a second photoelectric converter that generates charges by performing photoelectric conversion of the second wavelength light transmitted through the second filter;
a second microlens;
a third filter that is transmissive to the first wavelength of light having passed through the second microlens;
a third photoelectric converter that generates charges by performing photoelectric conversion of the first wavelength light transmitted through the third filter;
a fourth filter that is transmissive to the second wavelength of light having passed through the second microlens;
a fourth photoelectric converter that generates charges by performing photoelectric conversion of the second wavelength light transmitted through the fourth filter;
a first output unit that outputs a first signal based upon at least one of the charges generated by the first photoelectric converter and the charges generated by the third photoelectric converter; and
a second output unit that outputs a second signal based upon at least one of the charges generated by the second photoelectric converter and the charges generated by the fourth photoelectric converter.

US Pat. No. 10,218,940

VISION SYSTEM FOR VEHICLE WITH ADJUSTABLE CAMERA

MAGNA ELECTRONICS INC., ...

1. A vehicular vision system, said vehicular vision system comprising:a side-mounted camera disposed at a side of a vehicle equipped with said vehicular vision system, said side-mounted camera having a field of view exterior of the equipped vehicle;
wherein, responsive to the equipped vehicle traveling in a forward direction of travel at a forward traveling speed, the field of view of said side-mounted camera is adjustable between a more downward field of view, where said side-mounted camera captures image data at least representative of a ground region at the side of the equipped vehicle at which said side-mounted camera disposed, and a less downward field of view, where said side-mounted camera captures image data at least representative of regions further away from the equipped vehicle than the ground region at the side of the equipped vehicle at which said side-mounted camera disposed;
wherein, responsive to the forward traveling speed of the equipped vehicle, said vehicular vision system adjusts the field of view of said side-mounted camera to (i) the more downward field of view for capturing image data at least representative of the ground region at the side of the equipped vehicle at which said side-mounted camera disposed or (ii) the less downward field of view for capturing image data at least representative of regions further away from the equipped vehicle;
wherein, when the forward traveling speed of the equipped vehicle is at or below a threshold speed level, said side-mounted camera to adjusted to have the more downward field of view so as to capture image data at least representative of the ground region at the side of the equipped vehicle, said vehicular vision system uses image data captured by said side-mounted camera for displaying video images at a display device disposed in an interior cabin of the equipped vehicle that is viewable by a driver of the equipped vehicle who is driving the equipped vehicle;
wherein, when the forward traveling speed of the equipped vehicle is above the threshold speed level, said side-mounted camera is adjusted to have the less downward field of view so as to capture image data at least representative of regions further away from the equipped vehicle, image data captured by said side-mounted camera is processed at an image processor of said vehicular vision system for a driver assistance system of the equipped vehicle; and
wherein, when the forward traveling speed of the equipped vehicle is above the threshold level, and with said side-mounted camera adjusted to have the less downward field of view so as to capture image data at least representative of regions further away from the equipped vehicle, image data captured by said side-mounted camera is processed at said image processor of said vehicular vision system, and wherein, responsive to processing at said image processor of image data captured by said side-mounted camera, objects present in the less downward field of view of said side-mounted camera are detected.

US Pat. No. 10,218,938

METHODS AND SYSTEMS FOR MULTI-PANE VIDEO COMMUNICATIONS WITH PHOTO-BASED SIGNATURE VERIFICATION

POPIO IP HOLDINGS, LLC, ...

1. A method comprising:conducting a video chat between a mobile device and a support terminal via a first connection;
receiving, from the support terminal, a display element comprising an authentication element at the mobile device via a second connection during the video chat;
dividing, in response to receiving the display element, a display screen of the mobile device into a first pane that comprises the video chat and a second pane that comprises the authentication element;
detecting user input at the mobile device confirming the authentication element within the second pane during the video chat being provided in the first pane;
capturing, in response to detecting the user input confirming the authentication element during the video chat, an image of a user at the mobile device; and
providing the image of the user confirming the authentication element to the support terminal in connection with the confirmation of the authentication element.

US Pat. No. 10,218,937

VIDEO CALLING METHOD AND APPARATUS

TENCENT TECHNOLOGY (SHENZ...

1. A video calling method, comprising:obtaining a first video image acquired by a first terminal;
performing action recognition on the first video image; and
sending, in response to determining that an action recognition result matches a first preset action, a first preset animation corresponding to the first preset action and the first video image to a second terminal performing video calling with the first terminal for displaying by the second terminal,
wherein the method further comprises:
displaying an animation selection window in a video window of the first terminal;
determining, when receiving a first preset animation selection instruction that is input based on the animation selection window, a first preset action prompt template corresponding to the first preset animation selection instruction; and
displaying the first preset action prompt template in the video window of the first terminal, wherein
the first preset animation selection instruction corresponds to the first preset action and the first preset animation.

US Pat. No. 10,218,930

COUNTING CIRCUIT INCLUDING A PLURALITY OF LATCH CIRCUITS AND IMAGE SENSING DEVICE WITH THE COUNTING CIRCUIT

SK Hynix Inc., Gyeonggi-...

1. A counting circuit comprising:a sampling circuit configured to sample an inverted bit signal, which corresponds to any one of inverted signals of a bit signal and a previous bit signal, as the bit signal in response to a counting target clock signal;
a first latch circuit configured to latch the bit signal, as which the sampling circuit samples the inverted bit signal corresponding to the inverted signal of the bit signal during a first period, as the previous bit signal at a first time point in response to a first latch control signal, and provide the previous bit signal to the sampling circuit at a third time point in response to a load control signal;
a second latch circuit configured to latch the bit signal, as which the sampling circuit samples the inverted bit signal corresponding to the inverted signal of the bit signal during a second period, as a first counting bit signal at a second time point in response to a second latch control signal; and
a third latch circuit configured to latch the bit signal, as which the sampling circuit samples the inverted bit signal corresponding to the inverted signal of the previous bit signal during a third period, as a second counting bit signal at a fourth time point in response to a third latch control signal.

US Pat. No. 10,218,914

INFORMATION COMMUNICATION APPARATUS, METHOD AND RECORDING MEDIUM USING SWITCHABLE NORMAL MODE AND VISIBLE LIGHT COMMUNICATION MODE

PANASONIC INTELLECTUAL PR...

1. An apparatus, comprising:a display;
a processor; and
a recording medium having a program, the program causing the processor to execute operations including
obtaining a first image by image capture with a first exposure time by starting exposure for a plurality of exposure lines in an image sensor,
obtaining a second image including a plurality of bright lines, by capturing a subject changing in luminance by the image sensor with a second exposure time by starting exposure for the plurality of exposure lines in the image sensor, the second exposure time being set so that the plurality of bright lines corresponding to the plurality of exposure lines included in the image sensor appear in the second image according to a change in luminance of the subject,
obtaining information by demodulating data specified by a pattern of the plurality of bright lines included in the obtained second image, and
displaying the first image of the display a second time, instead of displaying the second image, when the image sensor receives the first image followed by the second image.

US Pat. No. 10,216,972

PIXEL ARCHITECTURE AND DRIVING SCHEME FOR BIOMETRIC SENSING

SYNAPTICS INCORPORATED, ...

1. A processing system for performing capacitive sensing, the processing system comprising:a controller circuit configured to apply, during a charge stage, a charging voltage to a first sensor electrode and a second sensor electrode, wherein the first sensor electrode neighbors the second sensor electrode in an array of sensor electrodes; and
a sensor circuit configured to, during a read stage:
drive the first sensor electrode to a reference voltage; and
measure a first charge stored on the first sensor electrode resulting from applying the charging voltage, wherein the controller circuit is configured to bias the second sensor electrode to the reference voltage during the read stage.

US Pat. No. 10,216,967

VOLATILE MEMORY-BASED DATA-TRANSFER DEVICE WITH AUTOMATIC AND USER-INITIATED ANTI-TAMPER PENALTIES

The United States of Amer...

13. A removable, volatile memory-based USB data transfer device, comprising:a housing having an integral serial protocol plug, wherein said serial protocol plug is adapted to removably attach to an external computer and, when attached to the external computer, draw electrical power from the external computer, receive data from the external computer, and transfer data to the external computer;
a volatile memory module integral with said housing and adapted to store data received through the serial protocol plug from the external computer when supplied with electrical power;
an onboard power storage device integral with said housing and configured to receive and store a finite supply of electrical power drawn through the serial protocol plug from the external computer and, when the serial protocol plug is not attached to the external computer, selectively supply stored electrical power to the volatile memory module;
an electrical switch integral with said housing and configured to interrupt the supply of electrical power from the onboard power storage device to the volatile memory module in response to manual actuation; and
a storage controller integral with said housing and adapted to direct the supply of electrical power from the onboard power storage device to the volatile memory module when the serial protocol plug is not attached to the external computer, wherein said storage controller is additionally adapted to interrupt the supply of electrical power from the onboard power storage device to the volatile memory module after a predetermined time period from at least one of data received through the serial protocol plug being stored on the volatile memory module and the serial protocol plug being disconnected from the external computer.

US Pat. No. 10,216,965

SYSTEMS AND METHODS FOR GENERATING PHYSICALLY UNCLONABLE FUNCTIONS FROM NON-VOLATILE MEMORY CELLS

STC.UNM, Albuquerque, NM...

1. A method for generating a physically unclonable bitstring, the method comprising:programming cells in a memory array to a first state;
for each cell in the memory array, measuring by a voltage-to-digital converter a value corresponding to a respective analog entropy source;
digitizing by the voltage-to-digital converter the value for each cell;
determining an approximate median value corresponding to the digitized values;
programming cells in the memory array having a value greater than the approximate median value to a second state; and
generating a bitstring by reading the states of cells in the memory array.

US Pat. No. 10,216,956

VIRTUALIZATION INPUT COMPONENT

Oath Inc., New York, NY ...

1. A system, comprising:a processor comprising hardware; and
memory comprising processor-executable instructions that when executed by the hardware processor cause implementation of a virtualization input component, hosted by a first device comprising personal information of a user, configured to:
establish a communication connection between the first device and a second device;
identify, on the first device, a user interface element and a second user interface element within a user interface of the second device, wherein the first device is a virtualized input device to the second device;
responsive to the user interface element having a visible text property and the personal information having a non-display privacy setting, determine that the user interface element is not a personal information input field for the personal information;
responsive to the second user interface element having a hidden text property and the personal information having the non-display privacy setting, determine that the second user interface element is the personal information input field identified for the personal information;
generate, on the first device, an input event comprising the personal information in response to determining the identified personal information input field of the second user interface element; and
send the input event over the established communication connection from the first device to the second device in association with the second user interface element, the input event invoking the second device to fill in the personal information input field with the personal information.

US Pat. No. 10,216,613

RESERVED PROCESS AND THREAD IDENTIFIERS FOR TRACING

INTERNATIONAL BUSINESS MA...

1. A computer-implemented method of debugging software code, the method comprising:storing a database table that specifies previous executions of one or more executables of the software code, one or more event handlers, one or more executable names, one or more reserved process identifiers (PID)'s, one or more thread identifiers (TID)'s and one or more use indicators and their associations with one another;
starting execution, using a processor, an instantiation of an executable within the software code;
determining whether the instantiation of the executable comprises an executable name that corresponds with an executable name entry in the database table;
determining whether an event handler is available for said executable name based on the database tables associations for said executable name;
assigning a reserved PID and one of the one or more TIDs associated with the executable name in the database table, to the instantiation of the executable; and
debugging the software code, wherein a trace is associated with the reserved PID and the one of the one or more TIDs following the execution of the instantiation of the executable.

US Pat. No. 10,216,233

FORMING FEATURES IN A CERAMIC COMPONENT FOR AN ELECTRONIC DEVICE

APPLE INC., Cupertino, C...

1. A method for forming a three-dimensional feature in a surface of a cover for an electronic device, comprising:removing material from the cover by rotating a spherical bristle brush including multiple abrasive bristles about a first axis, the outer periphery of the multiple abrasive bristles defines a spherical shape; and
while rotating the spherical bristle brush about the first axis, rotating the cover about a second axis that is orthogonal to the first axis; wherein
the spherical bristle brush contacts an entirety of the three-dimensional feature during the operations of removing the material and rotating the cover.

US Pat. No. 10,215,532

VISUAL DEVICE FOR DESIGNATING OBJECTIVES AND OBJECTIVE-DESIGNATION METHOD USING SAID DEVICE

SOFRESUD, La Seyne sur M...

1. A device for the designation of objectives, comprising a direct sighting member, associated with a gyroscopic unit providing a gyrometric trihedron with three axes not parallel to each other and coupled firstly tomeans for analysing the signals issuing from the sighting member, said means being able to determine the direction between the sighting member and said objectives and to transmit it to a distant control station provided with action means, and
secondly to means for recalibrating the gyroscopic unit,
wherein it further comprises image-acquisition means providing photography of the objectives, said acquisition means being associated with the direct-sighting member and coupled to software means for processing the images and to means for displaying said images,
wherein said gyroscopic unit comprises micro-electro-mechanical systems (MEMS) sensors combining said gyrometric trihedron and accelerometers.

US Pat. No. 10,215,522

ADJUSTABLE TRIGGER PULL FOR A CROSSBOW

ARCHERY INNOVATORS, LLC, ...

1. An adjustable trigger for a crossbow comprising:a linkage arm having a first end and a second end;
a string latch is capable of holding a string;
a sear lever is in contact with said string latch for preventing a release of the string from said string latch, said sear lever is not in contact with said string latch to allow a release of the string from said string latch;
a trigger lever includes a pivot point and at least two moment arm holes, said trigger lever is pivotally engaged with said crossbow at said pivot point, said first end of said linkage arm is pivotally engaged with one of said at least two moment arm holes, said second end of said linkage arm is pivotally engaged with said sear lever, a center point of said at least two moment arm holes are located on an end of an arc, said arc has an origin of a pivot point of said linkage arm and said sear lever, wherein a distance between said pivot point and a first moment arm hole is a distance TD?, a distance between said pivot point and a second moment arm hole is a distance TD?.

US Pat. No. 10,214,488

METHODS OF MANUFACTURING CERTAIN SUBSTITUTED SULFILIMINES

Dow AgroSciences LLC, In...

1. A method of preparing a sulfilimine of Formula (I),
wherein X represents halogen, C1-C4 alkyl or C1-C4 haloalkyl; comprising,
(a) mixing a solution cyanamide, a solution of hypochlorite, and a solvent in a first continuous loop reactor;
(b) transferring the mixture of Step (a) into a second continuous loop reactor;
(c) adding a sulfide of Formula (II) into the second continuous loop reactor which reacts with the mixture of Step (a) to form the sulfilimine,

wherein X is as previously defined; and
(d) decanting the aqueous phase giving an organic phase containing a sulfilimine of Formula (I).